These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
327 related items for PubMed ID: 35401817
1. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness. Lan J, Wei G, Liu J, Yang F, Sun R, Lu H. Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817 [Abstract] [Full Text] [Related]
2. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. Lu H, Xie Y, Tran L, Lan J, Yang Y, Murugan NL, Wang R, Wang YJ, Semenza GL. J Clin Invest; 2020 Sep 01; 130(9):4607-4623. PubMed ID: 32427586 [Abstract] [Full Text] [Related]
3. Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment. Lu H, Tran L, Park Y, Chen I, Lan J, Xie Y, Semenza GL. Cancer Res; 2018 Aug 01; 78(15):4191-4202. PubMed ID: 29880481 [Abstract] [Full Text] [Related]
4. Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. Lan J, Lu H, Samanta D, Salman S, Lu Y, Semenza GL. Proc Natl Acad Sci U S A; 2018 Oct 09; 115(41):E9640-E9648. PubMed ID: 30242135 [Abstract] [Full Text] [Related]
6. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, Semenza GL. Oncotarget; 2016 Oct 04; 7(40):64527-64542. PubMed ID: 27590511 [Abstract] [Full Text] [Related]
8. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Zhou L, Wang D, Sheng D, Xu J, Chen W, Qin Y, Du R, Yang X, He X, Xie N, Liu S, Zhang L. Theranostics; 2020 Oct 04; 10(5):2405-2421. PubMed ID: 32104513 [Abstract] [Full Text] [Related]
10. NARF is a hypoxia-induced coactivator for OCT4-mediated breast cancer stem cell specification. Yang Y, Chen C, Zuo Q, Lu H, Salman S, Lyu Y, Huang TY, Wicks EE, Jackson W, Datan E, Wang R, Wang Y, Le N, Zhu Y, Qin W, Semenza GL. Sci Adv; 2022 Dec 09; 8(49):eabo5000. PubMed ID: 36490339 [Abstract] [Full Text] [Related]
14. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S. Breast Cancer Res Treat; 2015 Jun 09; 151(2):281-94. PubMed ID: 25904215 [Abstract] [Full Text] [Related]
16. Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3. Seehawer M, Li Z, Nishida J, Foidart P, Reiter AH, Rojas-Jimenez E, Goyette MA, Yan P, Raval S, Munoz Gomez M, Cejas P, Long HW, Papanastasiou M, Polyak K. Nat Cell Biol; 2024 Jul 09; 26(7):1165-1175. PubMed ID: 38926506 [Abstract] [Full Text] [Related]
18. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer. De Santis F, Romero-Cordoba SL, Castagnoli L, Volpari T, Faraci S, Fucà G, Tagliabue E, De Braud F, Pupa SM, Di Nicola M. Cell Oncol (Dordr); 2022 Apr 09; 45(2):257-274. PubMed ID: 35357654 [Abstract] [Full Text] [Related]